The National Pharmaceutical Council (NPC), a health policy research organization dedicated to the advancement of good evidence, science and medical innovation, announced the appointment of Sharon Phares, PhD, MPH, as chief scientific officer.
Press Release
Washington, D.C. – January 4, 2022 – The National Pharmaceutical Council (NPC), a health policy research organization dedicated to the advancement of good evidence, science and medical innovation, today announced the appointment of Sharon Phares, PhD, MPH, as Chief Scientific Officer. Dr. Phares will replace Robert W. Dubois, MD, PhD, who is retiring from NPC at the end of February 2022.
Dr. Phares, who assumes the role today, will direct NPC’s research strategy and oversee the organization’s research on policy issues, including demystifying pharmaceutical pricing perceptions, addressing challenges of health technology assessments, and examining underlying issues of patient access and affordability.
Prior to joining NPC, Dr. Phares was the Senior Vice President of Research at Pharmaceutical Strategies Group (PSG), an EPIC company, where she developed and managed all research efforts, transforming research objectives into study designs, analytic plans, and survey tools, and translating research findings into actionable information to support both internal and external clients. She also serves as an Adjunct Assistant Professor of Medicine at the Washington University School of Medicine in St. Louis.
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More